Celgene Corporation #CELG and Bluebird bio, Inc. #BLUE announced updated data from their ongoing Phase I trial of bb2121 CAR T cell therapy, for the treatment of late-stage relapsed/refractory multiple myeloma. The data showed the median progression-free survival (PFS) estimate for patients in the dose-escalation phase was 11.8 months. Overall response rate of the highest dose was 95.5% with a complete response rate of 50%.
My little brother recently had treatment for Multiple Myeloma, and did a lot of research into these. Very good candidates. And any cancer drug is extremely expensive